SNV 1521
Alternative Names: SNV-1521Latest Information Update: 16 Mar 2024
At a glance
- Originator Synnovation Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Feb 2024 Synnovation Therapeutics has patent pending application for "Parp1 inhibitors" in Taiwan and multiple countries worldwide
- 02 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06220864)
- 24 Jan 2024 Preclinical trials in Solid tumours in USA (PO)